



IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

NASDAQ: **IDYA**

May 2023

IDEAYA Highlights

Breakthrough Science on transformative programs in precision medicine, including Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships with GlaxoSmithKline¹, including ~\$2 billion in potential cash milestones, Pfizer² and Amgen³

Strong Balance Sheet of ~\$539 million⁴ with capital efficient model, anticipated to fund operations into 2027

Analyst Coverage by Berenberg, Capital One, Citi, Goldman Sachs, Guggenheim, Jefferies, JP Morgan, Oppenheimer, RBC, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement;
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements;
- (3) Amgen Clinical Trial Collaboration and Supply Agreement;
- (4) Includes aggregate of ~\$351.2M cash, cash equivalents and marketable securities as of March 31, 2023 and ~\$188.7M estimated net proceeds from closing of underwritten public offering on April 27, 2023